UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported) March 1, 2016

 

 

 

Kewaunee Scientific Corporation 

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 0-5286 38-0715562
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

 

 

2700 West Front Street

Statesville, North Carolina

28677
(Address of principal executive offices) (Zip Code)

 

 

 

Registrant’s telephone number, including area code     704-873-7202

  

 

 

N/A 

(Former name or former address, if changed since last report.)

  

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

  

Item  2.02 Results of Operations and Financial Condition

  

On March 1, 2016, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter ended January 31, 2016. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

 

Item  9.01 Financial Statements and Exhibits

  

  (d) Exhibits:

  

  Exhibit No.  
     
        99.1 Press Release of Kewaunee Scientific Corporation dated March 1, 2016

  

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

      (Registrant)
      Kewaunee Scientific Corporation
       
Date:  March 1, 2016      /s/ Thomas D. Hull III
      Thomas D. Hull
      Vice President, Finance
      Chief Financial Officer

 

 



Exhibit 99.1
 

Kewaunee Scientific Reports Results for Third Quarter

STATESVILLE, N.C., March 1, 2016 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported results for its third quarter ended January 31, 2016.

Kewaunee Scientific Corporation

Sales for the quarter were $32,410,000, a 17% increase from sales of $27,754,000 in the prior year. Domestic sales for the quarter were $25,423,000, up 27% from sales of $20,025,000 in the third quarter of last year. International sales for the quarter were $6,987,000, down 10% from sales of $7,729,000 in the third quarter last year.

Net earnings for the quarter were $830,000, or $0.31 per diluted share, as compared to net earnings of $484,000, or $0.18 per diluted share, in the third quarter last year. Sales and earnings for the quarter were higher in comparison to the prior year period as the opportunities within the domestic market were stronger than is typical for our third quarter. International sales were down on a year-over-year basis due to the timing of a large order shipped during the third quarter of last year that did not repeat.

The Company's order backlog was $95.2 million at January 31, 2016 as compared to $78.0 million at January 31, 2015, and $92.4 million at October 31, 2015. Incoming orders for the Domestic business were strong during the quarter due to increased opportunities for laboratory furniture and scientific equipment; however, sales of education related products remained soft as many state and local governments continue to struggle financially. The International backlog also strengthened as the International team secured a number of new orders across all of our key International markets.

The Company's balance sheet and financial condition remain strong. Unrestricted cash on hand was $3,709,000 at the end of the quarter, as compared to $3,863,000 at the end of the third quarter last year. Working capital was $29,541,000 as compared to $27,352,000 at the end of the third quarter last year. Short-term debt and interest rate swaps were $5,538,000 at the end of the quarter, as compared to $1,036,000 at the end of the third quarter last year, and long-term debt was $3,455,000 as compared to $3,876,000.

"Historically, the third quarter is often Kewaunee's weakest; however, during the third quarter of fiscal year 2016, we were able to deliver strong year-over-year top line and earnings performance, improved margins, and continued growth of our backlog," said David M. Rausch, Kewaunee's President and Chief Executive Officer. "We are seeing continued strength from the laboratory furniture and casework marketplace as our customers continue to both invest in new facilities and upgrade existing facilities."

"Looking forward, we are focused on exceeding our customers' expectations as we continue to respond to market opportunities globally. We expect both the domestic and international laboratory casework marketplace will continue to be strong with improved demand for both new construction and renovation projects. We anticipate a strong fourth quarter in both sales and earnings."

About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com. `

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)














Three months ended


Nine months ended




 January 31,


 January 31,




2016


2015


2016


2015

Net sales



$    32,410


$    27,754


$    94,536


$    88,546

Cost of products sold


26,922


23,298


77,673


72,120

Gross profit



5,488


4,456


16,863


16,426

Operating expenses


4,441


3,872


13,163


12,170

Operating earnings


1,047


584


3,700


4,256

Other income


109


134


296


385

Interest expense


(83)


(91)


(236)


(274)

Earnings before income taxes


1,073


627


3,760


4,367

Income tax expense


225


109


1,242


1,361

Net earnings



848


518


2,518


3,006

Less: net earnings attributable to









    the noncontrolling interest


18


34


53


86

Net earnings attributable to 









    Kewaunee Scientific Corporation


$         830


$         484


$      2,465


$      2,920











Net earnings per share attributable to









    Kewaunee Scientific Corporation stockholders







       Basic



$        0.31


$        0.18


$        0.93


$        1.11

       Diluted



$        0.31


$        0.18


$        0.92


$        1.10











Weighted average number of common









shares outstanding









       Basic



2,682


2,628


2,661


2,625

       Diluted



2,699


2,659


2,683


2,656











Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

(in thousands)














January 31,


April 30,






2016


2015

Assets





(Unaudited)



Cash and cash equivalents




$      3,709


$      3,044

Restricted Cash




1,444


2,276

Receivables, less allowances




29,409


29,106

Inventories





16,154


12,745

Prepaid expenses and other current assets




1,705


1,591

    Total Current Assets




52,421


48,762

Net property, plant and equipment




14,381


14,523

Other assets





6,037


6,205

Total Assets





$    72,839


$    69,490









Liabilities and Equity







Short-term borrowings and interest rate swaps



$      5,538


$      4,955

Current portion of long-term debt




421


421

Accounts payable




12,215


11,232

Other current liabilities




4,706


4,447

    Total Current Liabilities




22,880


21,055

Other non-current liabilities




13,167


13,236

    Total Liabilities




36,047


34,291

Noncontrolling interest




282


323

Kewaunee Scientific Corporation equity




36,510


34,876

    Total Equity




36,792


35,199

Total Liabilities and Equity




$    72,839


$    69,490

Contact: 

Thomas D. Hull III


(704) 871-3290

Logo - http://photos.prnewswire.com/prnh/20160229/338700LOGO



Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.